Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Other Non Operating Income (2022 - 2025)

TScan Therapeutics (TCRX) has disclosed Other Non Operating Income for 4 consecutive years, with $881000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 111.73% to $881000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.4 million, a 32.11% decrease, with the full-year FY2025 number at $6.0 million, up 654.77% from a year prior.
  • Other Non Operating Income was $881000.0 for Q4 2025 at TScan Therapeutics, up from -$7.5 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $2.7 million in Q3 2024 to a low of -$7.5 million in Q4 2024.
  • A 4-year average of $390000.0 and a median of $881000.0 in 2025 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 2456.76% in 2023, then crashed 530.56% in 2024.
  • TScan Therapeutics' Other Non Operating Income stood at -$74000.0 in 2022, then surged by 2456.76% to $1.7 million in 2023, then plummeted by 530.56% to -$7.5 million in 2024, then skyrocketed by 111.73% to $881000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Other Non Operating Income are $881000.0 (Q4 2025), -$7.5 million (Q4 2024), and $2.7 million (Q3 2024).